ad 5

AD 5 is a bioactive chemical.

AD-5467 is a bioactive chemical.

D-I03 is a selective RAD52 inhibitor with a Kd of 25.8 µM. It specifically inhibits RAD52-dependent single-chain annealing (SSA) and D-loop formation, with IC50 values of 5 µM and 8 µM, respectively. D-I03 also inhibits the growth of BRCA1 and BRCA2 deficient cells and prevents the formation of damage-induced RAD52 foci, but does not affect RAD51 foci induced by Cisplatin.

AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.

Blonanserin (AD-5423) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.

IBR2 (Isoquinoline) is a potent and specific RAD51 inhibitor known for its ability to suppress RAD51-mediated DNA double-strand break repair. By interfering with RAD51 multimerization, accelerating proteasome-mediated RAD51 protein degradation, inhibiting cancer cell growth, and inducing apoptosis, IBR2 has proved to be an effective compound in these aspects.

Blonanserin is an antagonist of dopamine-D2 and serotonin-S2.

Emzadirib (RAD51-IN-2) is a potent inhibitor of RAD51, showing potential anticancer activity and useful for studying DNA damage repair.

Kartogenin (KGN) is an activator of the smad4/smad5 pathway, and promotes the selective differentiation of multipotent mesenchymal stem cells into chondrocytes.

PSMA-D5 exhibits a binding affinity for PSMA with a Ki of 0.21 nM and becomes useful for PSMA tracing following radiolabeling. When marked with [68Ga], PSMA-D5 contains a DOTA chelator, facilitating the convenient labeling with therapeutic radionuclides such as 177Lu and 225Ac. Additionally, [68Ga]-labeled PSMA-D5 demonstrates exceptional pharmacokinetic properties and significant tumor uptake in 22Rv1 tumors. This compound can be employed in the synthesis and research of radiolabeled conjugates (RDC).

RAD51-IN-9 (Compound 3a) is an inhibitor of RAD51, specifically blocking its binding to ssDNA, with an IC50 of 17.85 μM. The compound has an LD50 of 40.21 μM in HEK293 cells and can sensitize cells to mitomycin C.

BRCA2-RAD51-IN-2 (compound S-35d) is a BRCA2-RAD51 inhibitor that, when combined with 10 µM Olaparib, can inhibit homologous recombination repair.

AD57, as polypharmacological cancer therapeutic, is designed to regulate multiple targets related to cancer blocks the receptor tyrosine kinase RET in Drosophila (IC50: 2 nM). AD57 effectively suppresses tyrosine kinase RET, weakens the activity of numero

RI-1 (RAD51 inhibitor 1) is a RAD51 inhibitor (IC50: 5-30 μM).

Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.

RI-2 is an optimized RAD51 inhibitor with an IC50 of 44.17 μM in the standard DNA binding assay; specifically inhibits HR(Homologous recombination) repair in human cells.

6-Hydroxy-DOPA is an allosteric inhibitor of RAD52, it inhibits proliferation of BRCA-deficient cancer cells in vitro and also inhibits APE1.

AD5075 is a bioactive chemical.

Astragaloside II (Astrasieversianin VIII) is an effective MDR reversal agent and may be a potential adjunctive agent for hepatic cancer chemotherapy. Astragaloside II also induces osteogenic activities, differentiation, proliferation, and mineralization, through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways.

RAD51-IN-3, a Rad51 inhibitor, is chemically identified as (8aR,9R)-11'-chloro-6',8'-dihydroxy-2H,2'H-[3,8'-bi-1H-benzo[f]indene]-1,3,5',7'(4H,6H)-tetraone.

RAD51 Inhibitor B02 (B02) (B02) is an inhibitor of human RAD51 with an IC50 of 27.4 μM.

ML367 is a potent inhibitor of ATPase family AAA domain-containing protein 5 (ATAD5) stabilization and serves as a probe molecule with low micromolar inhibitory activity.

RAD51-IN-8, a new RAD51 binder, is a RAD51-BRCA2 inhibitor that disrupts the RAD51 BRCA2 protein-protein interaction in the micromolar range. This protein-protein interaction (PPI) inhibitor also demonstrates inhibitory activity for H4A4 with an EC50 value of 19 μM [1].

RAD51-IN-7 is a potent inhibitor of RAD51, a eukaryotic gene, with demonstrated research potential for mitochondrial deficiency disorders.